Erin Swinstead advises clients from biotechnology startups to large pharmaceutical and diagnostic companies on protecting their intellectual property (IP). Her experience includes developing patent strategies, patent drafting and prosecution, freedom-to-operate assessments, patent validity and infringement analyses, due diligence and litigation support. Erin counsels clients across a broad range of technologies, including:

CAR-T cell therapy technologies

Vaccines

Antibody therapeutics

Diagnostics

Gene therapies and protein therapeutics

Food products

Plant genetics

Drug delivery

Prior to joining Quarles, Erin completed her doctoral thesis and served as a postdoctoral fellow at the National Institutes of Health and National Cancer Institute. Her research in genetics and molecular biology focused on hormone-driven cancers, including breast cancer, in cell line and mouse models with an emphasis on the genomic effects of transcription factor and steroid receptor interactions at the chromatin level. She also has experience with Illumina-based next generation sequencing instruments and high-throughput siRNA screens.

Bar Admissions
U.S. Patent and Trademark Office Washington D.C. Wisconsin

Education
Adelaide University (Ph.D., 2014)

Molecular Biology

Adelaide University (2010)

Georgetown University Law Center (J.D., 2024)

University of South Australia (B.L.M., 2008)

"Chromatin reprogramming in breast cancer" "Identification of a novel GR-ARID1a-P53BP1 protein complex involved in DNA damage repair and cell cycle regulation" "Meta-analysis of Chromatin Programming by Steroid Receptors" "Molecular and structural basis of androgen receptor responses to dihydrotestosterone, medroxyprogesterone acetate and ?4-tibolone" "Pioneer factors and ATP-dependent chromatin remodeling factors interact dynamically: A new perspective" "Steroid receptor crosstalk in breast cancer cell" "Steroid Receptors Reprogram FoxA1 Occupancy through Dynamic Chromatin Transitions" "Transcription factor assisted loading and enhancer dynamics dictate the hepatic fasting response"